Last reviewed · How we verify

NCT05889806

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)

ENROLLING BY INVITATION Last updated 5 June 2023
What this trial tests

trial testing Observational Study Only. NO Intervention. in Oncology in 10,000 participants. Enrolling by invitation.

Timeline
10 May 2023
Primary endpoint
10 May 2043
10 June 2043

Quick facts

Lead sponsorAudubon Bioscience
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment10,000
Start date10 May 2023
Primary completion10 May 2043
Estimated completion10 June 2043
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Audubon Bioscience

Who can join

18 and older, any sex, with Oncology or Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations. The Study is designed to discover biomarkers, develop and validate diagnostic assays, instruments and therapeutics as well as other medical research. Specifically, researchers may analyze proteins, RNA, DNA copy number changes, including large and small (1,000-100,000 kb) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both diseased tissue and case-matched germline DNA from Subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Oncology

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05889806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing